Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-005413-23
    Sponsor's Protocol Code Number:CY4031
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-02-16
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-005413-23
    A.3Full title of the trial
    A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)
    Studio di fase 3, multinazionale, in doppio cieco, randomizzato, controllato verso placebo, stratificato, a gruppi paralleli per valutare la sicurezza, la tollerabilità e l’effetto di tirasemtiv in pazienti con sclerosi laterale amiotrofica (SLA).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)
    Indagine ventilatoria del Tirasemtiv e valutazione degli indici longitudinali dopo il trattamento per un anno (VITALITY-ALS)
    A.3.2Name or abbreviated title of the trial where available
    -
    -
    A.4.1Sponsor's protocol code numberCY4031
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02496767
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCYTOKINETICS, INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCytokinetics, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCytokinetics, Inc.
    B.5.2Functional name of contact pointMedical Affairs
    B.5.3 Address:
    B.5.3.1Street Address280 East Grand Avenue
    B.5.3.2Town/ citySouth San Francisco, California
    B.5.3.3Post code94080
    B.5.3.4CountryUnited States
    B.5.4Telephone number0016506242929
    B.5.5Fax number00
    B.5.6E-mailmedicalaffairs@cytokinetics.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/12/970
    D.3 Description of the IMP
    D.3.1Product nameTirasemtiv
    D.3.2Product code CK-2017357
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTirasemtiv
    D.3.9.1CAS number 1005491-05-3
    D.3.9.2Current sponsor codeCK-2017357
    D.3.9.3Other descriptive name6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
    D.3.9.4EV Substance CodeSUB93455
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number125
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Amyotrophic Lateral Sclerosis (ALS)
    Sclerosi laterale amiotrofica (SLA)
    E.1.1.1Medical condition in easily understood language
    Amyotrophic lateral sclerosis, or ALS, is a disease of the nerve cells in the brain and spinal cord that control voluntary muscle movement.
    Sclerosi laterale amiotrofica o SLA, che è una patologia delle cellule nervose del cervello e del midollo spinale che controllano il movimento volontario del muscolo.
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10002026
    E.1.2Term Amyotrophic lateral sclerosis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to assess the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
    L'obiettivo principale è quello di valutare l'efficacia di tirasemtiv verso placebo sulla funzione respiratoria in pazienti con SLA
    E.2.2Secondary objectives of the trial
    Secondary objectives include:
    • Evaluation of alternative methods to assess the effect of tirasemtiv versus placebo on percent predicted SVC in patients with ALS
    • Assessment of the effect of tirasemtiv versus placebo on other clinical measures related to the progressive decline in respiratory function in patients with ALS
    • Assessment of the effect of tirasemtiv versus placebo on measures of skeletal muscle function in patients with ALS
    Gli obiettivi secondari includono:
    • Valutazione di metodi alternativi per valutare l'efficacia di tirasemtiv verso placebo della percentuale predetta di SVC in pazienti con SLA
    • Valutazione dell'efficacia di tirasemtiv verso placeboi su misure cliniche correlate al declino della funzione respiratoria in pazienti con SLA
    • Valutazione dell'efficacia di tirasemtiv verso placebo su misure della funzione muscolare scheletrica in pazienti affetti da SLA
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Biomarker Sample Collection
    Biomarkers are objective measures or indicators of normal biological processes, pathological processes or pharmacological responses to a
    therapeutic intervention. Biomarker development may be useful in developing markers to identify disease subtypes, to guide therapy, or predict disease severity. Where authorized by the applicable IRB/EC/REB approved informed consent, blood samples for biomarker development will be collected at the time points below:
    - Day 1
    - Week 8
    - Week 16
    - Week 24
    - Week 32
    - Week 40
    - Week 48
    Plasma samples will be stored for future biomarker analyses and will NOT be used for pharmacogenomic testing.
    Biomarker raccolta campione.
    I Biomarker sonomisure oggettive o indicatori di normali processi biologici, di processi patologici o di risposte farmacologiche in seguito ad un intervento terapeutico. Lo sviluppo del Biomarker può essere utile per lo sviluppo di markers che servono per identificare I sottotipi di una patologia, indirizzare una terapia o per predire la severità di una patologia. Laddove il CE avrà approvato il consenso informato, I campioni di sangue per lo sviluppo dei biomarker saranno raccolti secondo le seguenti tempistiche:
    - Giorno 1
    - Settimana 8
    - Settimana 16
    - Settimana 24
    - Settimana 32
    - Settimana 40
    - Settimana 48
    I campioni di plasma saranno conservati per le analisi future dei biomarker e non verranno usati per test di farmacogenomica.
    E.3Principal inclusion criteria
    1. Able to comprehend and willing to sign an Informed Consent Form (ICF)
    2. Male or female 18 years of age or older
    3. A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria) ≤ 24 months prior to screening
    4. Upright SVC ≥ 70 % of predicted for age, height and sex
    5. Able to swallow tablets without crushing, and in the opinion of the Investigator, is expected to continue to be able to do so during the trial
    6. A caregiver if one is needed
    7. Clinical laboratory findings within the normal range or, if outside the normal range, deemed not clinically significant by the Investigator
    8. Male patients must agree for the duration of the study and 10 weeks after the end of the study to use a condom during sexual intercourse with female partners who are of childbearing potential (i.e., following menarche until post-menopausal if not anatomically and physiologically incapable of becoming pregnant) and to have female partners use an additional effective means of contraception (e.g., diaphragm plus spermicide, or oral contraceptives) or the male patient must agree to abstain from sexual intercourse during and for 10 weeks after the end of the study, unless the male patient has had a vasectomy and confirmed sperm count is zero
    9. Female patients must be post-menopausal (≥ 1 year) or sterilized, or, if of childbearing potential, not be breastfeeding, have a negative pregnancy test, have no intention to become pregnant during the course of the study, and use effective contraceptive drugs or devices while requiring male partner to use a condom for the duration of the study and for 10 weeks after the end of the study
    10. Patients must be either on a stable dose of riluzole 50 mg twice daily for at least 30 days prior to screening or have not taken riluzole for at least 30 days prior to screening and are willing not to begin riluzole use until they complete study drug dosing
    1. In grado di comprendere e disposto a firmare un modulo di consenso informato (Informed Consent Form, ICF)
    2. Pazienti di ambo i sessi di almeno 18 anni di età
    3. Diagnosi di SLA familiare o sporadica (definita come possibile, probabile inbase ai dati di laboratorio, probabile o certa in base ai criteri per la diagnosi della SLA secondo la World Federation of Neurology El Escorial) da ≤24 mesi prima dello screening
    4. SVC in posizione eretta ≥70% del valore predetto per età, altezza e sesso
    5. In grado di ingerire compresse senza frantumarle e, secondo il parere dello sperimentatore, si prevede continuerà ad essere in grado di farlo durante la sperimentazione
    6. Un caregiver, se necessario
    7. Risultati di laboratorio clinico che rientrano nell’intervallo normale o, se al di fuori dell’intervallo normale, ritenuti non clinicamente significativi dallo sperimentatore
    8. I pazienti di sesso maschile devono acconsentire, per la durata dello studio e per 10 settimane dopo la conclusione dello studio, a usare un preservativo durante i rapporti sessuali con partner di sesso femminile potenzialmente fertili (ossia dal post-menarca fino alla menopausa se non anatomicamente e fisiologicamente incapaci di iniziare una gravidanza) e far usare alle partner di sesso femminile un mezzo contraccettivo efficace supplementare (es. diaframma più spermicida o contraccettivi orali) oppure i pazienti di sesso maschile devono acconsentire ad astenersi dai rapporti sessuali durante e per 10 settimane dopo la conclusione dello studio, salvo il paziente abbia subito una vasectomia e la conta spermatica sia pari a zero, confermata.
    9. Le pazienti di sesso femminile devono essere in menopausa (da ≥1 anno) o sterilizzate oppure, se potenzialmente fertili, non allattare, avere un test di gravidanza negativo, non avere intenzione di iniziare una gravidanza durante lo studio e usare farmaci o dispositivi contraccettivi efficaci, richiedendo ai partner di sesso maschile di usare un preservativo per la durata dello studio e per 10 settimane dopo la conclusione dello studio
    10. I pazienti devono assumere una dose stabile di riluzolo 50 mg due volte al giorno da almeno 30 giorni prima dello screening oppure non aver assunto riluzolo per almeno 30 giorni prima dello screening ed essere disposti a non iniziare ad assumere riluzolo fino a quando non completano l’assunzione del farmaco dello studio
    E.4Principal exclusion criteria
    1. At the time of screening, any use of non-invasive positive pressure ventilation (NIPPV, e.g. continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BiPAP]) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation
    2. Patients with a diaphragm pacing system (DPS) at study entry or who anticipate DPS placement during the course of the study
    3. BMI of 20.0 kg/m2 or lower
    4. Unwilling or unable to discontinue tizanidine and theophylline-containing medications during study participation
    5. Serum chloride outside the normal reference range
    6. Neurological impairment due to a condition other than ALS, including history of transient ischemic attack within the past year
    7. Presence at screening of any medically significant cardiac, pulmonary, GI, musculoskeletal, or psychiatric illness that might interfere with the patient’s ability to comply with study procedures or that might confound the interpretation of clinical safety or efficacy data, including, but not limited to:
    a. Poorly controlled hypertension
    b. NYHA Class II or greater congestive heart failure
    c. Chronic obstructive pulmonary disease or asthma requiring daily use bronchodilator medications
    d. GI disorder that might impair absorption of study drug
    e. History of significant liver disease defined by bilirubin > 2 times the upper limit of normal (ULN) or ALT or AST > 3 times the ULN on repeat testing
    f. Poorly controlled diabetes mellitus
    g. History of vertigo within three months of study entry
    h. History of syncope without an explainable or treated cause
    i. History of untreated intracranial aneurysm or poorly controlled seizure disorder
    j. Amputation of a limb
    k. Cognitive impairment, related to ALS or otherwise, sufficient to impair the patient’s ability to give informed consent and to understand and/or comply with study procedures
    l. Cancer with metastatic potential (other than basal cell carcinoma, carcinoma in situ of the cervix, or squamous cell carcinoma of the skin excised with clean margins) diagnosed and treated within the last two years
    m. Any other condition, impairment or social circumstance that, in the opinion of the Investigator, would render the patient not suitable to participate in the study
    n. Patient judged to be actively suicidal or a suicide risk by the Investigator
    8. Has taken any investigational study drug within 30 days or five half-lives of the prior agent, whichever is greater, prior to dosing
    9. Prior participation in any form of stem cell therapy for the treatment of ALS
    10. Previously received tirasemtiv in any previous clinical trial
    1. Al momento dello screening, eventuale uso di ventilazione a pressione positiva non invasiva (non-invasive positive pressure ventilation, NIPPV, es. ventilazione a pressione positiva continua delle vie aree [continous positive airway pressure, CPAP] o a due livelli di pressione positiva delle vie aree [bi-level positive airway pressure, BiPAP]) per qualsiasi porzione della giornata oppure ventilazione meccanica mediante tracheostomia oppure qualsiasi forma di somministrazione di ossigeno
    2. Pazienti con un sistema di pacing diaframmatico (diaphgram pacing system, DPS) al momento dell’ingresso nello studio o che prevedono un impianto di DPS durante lo studio
    3. BMI di 20,0 kg/m2 o inferiore
    4. Non disposto o non in grado di interrompere l’assunzione di farmaci contenenti tizanidina e teofillina durante la partecipazione allo studio
    5. Cloruro di sodio al di fuori dell’intervallo di riferimento normale
    6. Compromissione neurologica a causa di una condizione diversa dalla SLA, compresa anamnesi di attacco ischemico transitorio nell’ultimo anno
    7. Presenza allo screening di eventuali patologie cardiache, polmonari, GI, muscoloscheletriche o psichiatriche significative dal punto di vista medico che potrebbero interferire con la capacità del paziente di aderire alle procedure dello studio o che potrebbero confondere l’interpretazione dei dati clinici di sicurezza o efficacia, comprese, senza limitarsi a:
    e. Ipertensione scarsamente controllata
    f. Insufficienza cardiaca di classe NYHA II o superiore
    g. Pneumopatia cronica ostruttiva o asma che richiede uso quotidiano di farmaci broncodilatatori
    h. Disturbo GI che potrebbe compromettere l’assorbimento del farmaco dello studio
    i. Anamnesi di malattia epatica significativa definita come bilirubina >2 volte il limite superiore della normalità (upper limit of normal, ULN) o ALT o AST >3 volte l’ULN in test ripetuti
    j. Diabete mellito scarsamente controllato
    k. Anamnesi di vertigini negli ultimi tre mesi prima dell’ingresso nello studio
    l. Anamnesi di sincope senza una causa spiegabile o trattata
    m. Anamnesi di aneurisma intracranico non trattato o disturbo epilettico scarsamente controllato
    n. Amputazione di un arto
    o. Compromissione cognitiva, correlata alla SLA o meno, sufficiente a compromettere la capacità del paziente di fornire consenso informato e di comprendere e/o aderire alle procedure dello studio
    p. Tumore con potenziale metastatico (diverso dal carcinoma a cellule basali, carcinoma in situ della cervice o carcinoma a cellule squamose della cute escisso con margini puliti) diagnosticato e trattato negli ultimi due anni
    q. Qualsiasi altra condizione, compromissione o circostanza sociale che, nell’opinione dello sperimentatore, renderebbe il paziente non adatto alla partecipazione allo studio
    r. Paziente giudicato attivamente suicida o a rischio di suicidio da parte dello sperimentatore
    8. Ha assunto qualsiasi farmaco sperimentale entro 30 giorni o cinque emivite dell’agente, a seconda di quale periodo sia maggiore, prima del trattamento
    9. Precedente partecipazione in qualsiasi forma di terapia con cellule staminali per il trattamento della SLA
    10. Ricevimento precedente di tirasemtiv in qualsiasi precedente sperimentazione clinica
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is the change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted SVC.
    L’endpoint primario è la variazione, dal basale alla Settimana 24, della fase in doppio cieco, controllato verso placebo, della percentuale predetta della capacità vitale lenta (SVC)
    E.5.1.1Timepoint(s) of evaluation of this end point
    week 24
    settimana 24
    E.5.2Secondary end point(s)
    The following secondary endpoints are listed in the sequence that they will be analyzed in a closed testing procedure if the primary efficacy analysis is met:
    1. Time to the first occurrence of a decline from baseline in percent predicted SVC ≥ 20 percentage points or the onset of respiratory insufficiency or death during all 48 weeks of double-blind, placebo-controlled treatment
    2. Time to the first occurrence of a decline in SVC to ≤ 50% predicted or the onset of respiratory insufficiency (defined as tracheostomy or the
    use of non-invasive ventilation for ≥ 22 hours per day for ≥ 10 consecutive days) or death during all 48 weeks of double-blind, placebocontrolled
    treatment
    3. Time to the first occurrence of the first use of mechanical ventilator assistance or death during all 48 weeks of double-blind, placebocontrolled
    treatment
    4. Time to the first occurrence of a decline in the respiratory components of the ALSFRS-R (i.e., items 10, 11, and 12) or death during all 48 weeks
    of double-blind, placebo-controlled treatment
    5. Slope of the change from baseline in mega-score of muscle strength from baseline to 24 weeks of the randomized, double-blind, placebo-controlled
    phase
    I seguenti endpoint secondari sono elencati nell’ordine in cui verranno analizzati mediante una procedura di test chiuso se l’analisi di efficacia primaria viene soddisfatta come definito nel protocollo.
    1. Tempo al primo evento di declino dal basale della percentuale predetta della SVC di ≥20 punti percentuali o insorgenza di insufficienza respiratoria o decesso durante tutte le 48 settimane del trattamento in doppio cieco, controllato verso placebo
    2. Tempo al primo evento di declino della SVC a valori ≤ 50% del valore predetto o insorgenza di insufficienza respiratoria (definita come tracheostomia o uso di ventilazione non invasiva per ≥ 22 ore al giorno per ≥10 giorni consecutivi) o decesso durante tutte le 48 settimane del trattamento in doppio cieco, controllato verso placebo
    3. Tempo al primo evento del primo uso di ventilazione meccanica assistita o decesso durante tutte le 48 settimane del trattamento in doppio cieco, controllato verso placebo
    4. Tempo al primo evento di declino delle componenti respiratorie dell’ALSFRS-R (cioè item 10, 11 e 12) o decesso durante tutte le 48 settimane del trattamento in doppio cieco, controllato verso placebo
    5. Pendenza della variazione rispetto al basale nel mega-punteggio della forza muscolare, dal basale a 24 settimane della fase randomizzata, in doppio cieco, controllata verso placebo
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 24, Week 48
    Settimana 24, Settimana 48
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA24
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Canada
    France
    Germany
    Ireland
    Italy
    Netherlands
    Portugal
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 1
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 430
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 170
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Yes
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 195
    F.4.2.2In the whole clinical trial 600
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-05-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-04-07
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 17:23:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA